Caged protein nanoparticles for drug delivery

Current Opinion in Biotechnology

Volumn 28, Issue , 2014, Pages 75-82

  Molino, Nicholas M ^a   Wang, Szu Wen ^a  

^a University of California at Irvine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIRABLE FEATURES; IMMUNO MODULATIONS; PROTEIN ENGINEERING; PROTEIN NANOPARTICLES; THERAPEUTIC COMPOUNDS; THERAPEUTIC EFFICACY; THERAPEUTIC MOLECULES; THERAPEUTIC TARGETS;

BIODEGRADATION; DRUG DELIVERY; MOLECULAR BIOLOGY; NANOPARTICLES; PROTEINS;

LOADING;

CAGED PROTEIN NANOPARTICLE; DOXORUBICIN; MACROGOL; NANOPARTICLE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG TARGETING; IMMUNE RESPONSE; NANOENCAPSULATION; NANOENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN IMMOBILIZATION; REVIEW; STRUCTURE ANALYSIS; VIRUS LIKE AGENT;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; NANOPARTICLES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 84891820543     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2013.12.007     Document Type: Review

References (69)

1. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
2. Maham A., Tang Z., Wu H., Wang J., Lin Y. Protein-based nanomedicine platforms for drug delivery. Small 2009, 5:1706-1721.
3. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
4. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
5. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
6. Yildiz I., Shukla S., Steinmetz N.F. Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 2011, 22:901-908.
7. Uchida M., Klem M.T., Allen M., Suci P., Flenniken M., Gillitzer E., Varpness Z., Liepold L.O., Young M., Douglas T. Biological containers: protein cages as multifunctional nanoplatforms. Adv Mater 2007, 19:1025-1042.
8. Smith M.T., Hawes A.K., Bundy B.C. Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr Opin Biotechnol 2013, 24:620-626.
9. Wu M., Brown W.L., Stockley P.G. Cell-specific delivery of bacteriophage-encapsidated ricin A chain. Bioconjug Chem 1995, 6:587-595.
10. Ren D.M., Kratz F., Wang S.W. Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 2011, 7:1051-1060.
11. Aljabali A.A., Shukla S., Lomonossoff G.P., Steinmetz N.F., Evans D.J. CPMV-DOX delivers. Mol Pharm 2013, 10:3-10.
12. Heilbronn R., Weger S. Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol 2010, 143-170.
13. Plummer E.M., Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010.
14. Ren D.M., Dalmau M., Randall A., Shindel M.M., Baldi P., Wang S.W. Biomimetic design of protein nanomaterials for hydrophobic molecular transport. Adv Funct Mater 2012, 22:3170-3180.
15. Worsdorfer B., Woycechowsky K.J., Hilvert D: Directed evolution of a protein container. Science 2011, 331:589-592.
16. Franco D., Liu W., Gardiner D.F., Hahn B.H., Ho D.D. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J Acquir Immune Defic Syndr 2011, 56:393-400.
17. Jeon J.O., Kim S., Choi E., Shin K., Cha K., So I.S., Kim S.J., Jun E., Kim D., Ahn H.J., et al. Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity. ACS Nano 2013.
18. Juarez V., Pasolli H.A., Hellwig A., Garbi N., Arregui A.C. Virus-like particles harboring CCL19 IL-2 and HPV16 E7 elicit protective T cell responses in HLA-A2 Transgenic mice. Open Virol J 2012, 6:270-276.
19. Kaczmarczyk S.J., Sitaraman K., Young H.A., Hughes S.H., Chatterjee DK: Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 2011, 108:16998-17003.
20. Zhang R., Zhang S., Li M., Chen C., Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010, 28:5114-5127.
21. Rhee J.K., Baksh M., Nycholat C., Paulson J.C., Kitagishi H., Finn M.G. Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules 2012, 13:2333-2338.
22. Shan L., Cui S., Du C., Wan S., Qian Z., Achilefu S., Gu Y. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012, 33:146-162.
23. Suci P., Kang S., Gmur R., Douglas T., Young M. Targeted Delivery of a Photosensitizer to Aggregatibacter actinomycetemcomitans biofilm. Antimicrob Agents Chemother 2010, 54:2489-2496.
24. Abbing A., Blaschke U.K., Grein S., Kretschmar M., Stark C.M., Thies M.J., Walter J., Weigand M., Woith D.C., Hess J., et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 2004, 279:27410-27421.
25. Zhao Q., Chen W., Chen Y., Zhang L., Zhang J., Zhang Z. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug Chem 2011, 22:346-352.
26. Zochowska M., Paca A., Schoehn G., Andrieu J.P., Chroboczek J., Dublet B., Szolajska E. Adenovirus dodecahedron, as a drug delivery vector. PLoS One 2009, 4:e5569.
27. Flenniken M.L., Liepold L.O., Crowley B.E., Willits D.A., Young M.J., Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) 2005, 447-449.
28. Toita R., Murata M., Abe K., Narahara S., Piao J.S., Kang J.H., Ohuchida K., Hashizume M. Biological evaluation of protein nanocapsules containing doxorubicin. Int J Nanomed 2013, 8:1989-1999.
29. Kovacs E.W., Hooker J.M., Romanini D.W., Holder P.G., Berry K.E., Francis MB: Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjugate Chem 2007, 18:1140-1147.
30. Kang Y.J., Park D.C., Shin H.H., Park J., Kang S. Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery nanoplatform. Biomacromolecules 2012, 13:4057-4064.
31. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., Bachmann MF: Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004, 172:1777-1785.
32. Yang Z., Wang X.Y., Diao H.J., Zhang J.F., Li H.Y., Sun H.Z., Guo ZJ: Encapsulation of platinum anticancer drugs by apoferritin. Chem Commun 2007, 3453-3455.
33. Choi K.M., Choi S.H., Jeon H., Kim I.S., Ahn H.J. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano 2011, 5:8690-8699.
34. Yildiz I., Lee K.L., Chen K., Shukla S., Steinmetz NF: Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery. J Control Release 2013, 172:568-578.
35. Zeng Q., Wen H., Wen Q., Chen X., Wang Y., Xuan W., Liang J., Wan S. Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials 2013, 34:4632-4642.
36. Liu X.Y., Wei W., Huang S.J., Lin S.S., Zhang X., Zhang C.M., Du Y.G., Ma G.H., Li M., Mann S., et al. Bio-inspired protein-gold nanoconstruct with core-void-shell structure: beyond a chemo drug carrier. J Mater Chem B 2013, 1:3136-3143.
37. Ma-Ham A.H., Wu H., Wang J., Kang X.H., Zhang Y.Y., Lin Y.H. Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA. J Mater Chem 2011, 21:8700-8708.
38. Ren Y., Wong S.M., Lim L.Y. Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug Chem 2007, 18:836-843.
39. Zhen Z.P., Tang W., Chen H.M., Lin X., Todd T., Wang G., Cowger T., Chen X.Y., Xie J. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 2013, 7:4830-4837.
40. Ashley C.E., Carnes E.C., Phillips G.K., Durfee P.N., Buley M.D., Lino C.A., Padilla D.P., Phillips B., Carter M.B., Willman C.L., et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011, 5:5729-5745.
41. Galaway F.A., Stockley PG: MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Mol Pharm 2013, 10:59-68.
42. Pan Y., Jia T.T., Zhang Y., Zhang K., Zhang R., Li J.M., Wang LN: MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomed 2012, 7:5957-5967.
43. Pan Y., Zhang Y., Jia T., Zhang K., Li J., Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J 2012, 279:1198-1208.
44. Wu M., Sherwin T., Brown W.L., Stockley P.G. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 2005, 1:67-76.
45. Niikura K., Sugimura N., Musashi Y., Mikuni S., Matsuo Y., Kobayashi S., Nagakawa K., Takahara S., Takeuchi C., Sawa H., et al. Virus-like particles with removable cyclodextrins enable glutathione-triggered drug release in cells. Mol Biosyst 2013, 9:501-507.
46. Lockney D.M., Guenther R.N., Loo L., Overton W., Antonelli R., Clark J., Hu M., Luft C., Lommel S.A., Franzen S. The Red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle. Bioconjug Chem 2011, 22:67-73.
47. Chou M.I., Hsieh Y.F., Wang M., Chang J.T., Chang D., Zouali M., Tsay G.J. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. J Biomed Sci 2010, 17:51.
48. Ji X.T., Huang L., Huang H.Q. Construction of nanometer cisplatin core-ferritin (NCC-F) and proteomic analysis of gastric cancer cell apoptosis induced with cisplatin released from the NCC-F. J Proteomics 2012, 75:3145-3157.
49. Choi S.H., Choi K., Kwon I.C., Ahn H.J. The incorporation of GALA peptide into a protein cage for an acid-inducible molecular switch. Biomaterials 2010, 31:5191-5198.
50. Dalmau M., Lim S.R., Wang SW: Design of a pH-dependent molecular switch in a caged protein platform. Nano Lett 2009, 9:160-166.
51. Kaiser C.R., Flenniken M.L., Gillitzer E., Harmsen A.L., Harmsen A.G., Jutila M.A., Douglas T., Young M.J. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomed 2007, 2:715-733.
52. Singh P., Prasuhn D., Yeh R.M., Destito G., Rae C.S., Osborn K., Finn M.G., Manchester M. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 2007, 120:41-50.
53. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
54. Speiser D.E., Schwarz K., Baumgaertner P., Manolova V., Devevre E., Sterry W., Walden P., Zippelius A., Conzett K.B., Senti G., et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010, 33:848-858.
55. Choi K.M., Kim K., Kwon I.C., Kim I.S., Ahn HJ: Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. Mol Pharm 2013, 10:18-25.
56. Stephanopoulos N., Tong G.J., Hsiao S.C., Francis M.B. Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Nano 2010, 4:6014-6020.
57. Ren D.M., Kratz F., Wang S.W. Engineered drug-protein nanoparticle complexes for folate receptor targeting. Biochem Eng J 2013, in press.
58. Suci P.A., Varpness Z., Gillitzer E., Douglas T., Young M. Targeting and photodynamic killing of a microbial pathogen using protein cage architectures functionalized with a photosensitizer. Langmuir 2007, 23:12280-12286.
59. Steinmetz N.F., Manchester M. PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 2009, 10:784-792.
60. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999, 10:1349-1358.
61. Molino N.M., Bilotkach K., Fraser D.A., Ren D.M., Wang SW: Complement activation and cell uptake responses toward polymer-functionalized protein nanocapsules. Biomacromolecules 2012, 13:974-981.
62. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J Control Release 2013, 172:38-47.
63. Cho S.K., Kwon Y.J. Simultaneous gene transduction and silencing using stimuli-responsive viral/nonviral chimeric nanoparticles. Biomaterials 2012, 33:3316-3323.
64. Sampath S., Carrico C., Janes J., Gurumoorthy S., Gibson C., Melcher M., Chitnis C.E., Wang R., Schief W.R., Smith J.D. Glycan masking of Plasmodium vivax duffy binding protein for probing protein binding function and vaccine development. PLoS Pathog 2013, 9:e1003420.
65. Molino N.M., Anderson A.K.L., Nelson E.L., Wang S.W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano 2013, in press.
66. King N.P., Sheffler W., Sawaya M.R., Vollmar B.S., Sumida J.P., Andre I., Gonen T., Yeates T.O., Baker D. Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science 2012, 336:1171-1174.
67. Goldinger S.M., Dummer R., Baumgaertner P., Mihic-Probst D., Schwarz K., Hammann-Haenni A., Willers J., Geldhof C., Prior J.O., Kundig T.M., et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol 2012, 42:3049-3061.
68. Pokorski J.K., Hovlid M.L., Finn M.G. Cell targeting with hybrid Qbeta virus-like particles displaying epidermal growth factor. Chembiochem 2011, 12:2441-2447.
69. Kang H.J., Kang Y.J., Lee Y.M., Shin H.H., Chung S.J., Kang S. Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform. Biomaterials 2012, 33:5423-5430.